Blinatumomab (English Wikipedia)
Analysis of information sources in references of the Wikipedia article "Blinatumomab" in English language version.
refsWebsite
Global rank
English rank
3,984th place
2,622nd place
3,257th place
3,398th place
1st place
1st place
low place
low place
ama-assn.org
- "Blinatumomab" (PDF). United States Adopted Names Council » Adopted Names. American Medical Association. 2008. N08/16.(registration required)
amgen.com
- "Amgen Receives FDA Breakthrough Therapy Designation For Investigational BiTE Antibody Blinatumomab In Acute Lymphoblastic Leukemia" (Press release). Amgen. 1 July 2014.
- "Amgen's BiTE Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia" (Press release). Amgen. 9 October 2014.
bbc.com
- "Exciting new cancer drug kinder than chemotherapy". BBC News. 17 January 2024. Retrieved 17 January 2024.
canada.ca
- "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.
doi.org
- Mølhøj M, Crommer S, Brischwein K, Rau D, Sriskandarajah M, Hoffmann P, et al. (March 2007). "CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis". Molecular Immunology. 44 (8): 1935–43. doi:10.1016/j.molimm.2006.09.032. PMID 17083975.
- Jen EY, Xu Q, Schetter A, Przepiorka D, Shen YL, Roscoe D, et al. (January 2019). "FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease". Clinical Cancer Research. 25 (2): 473–477. doi:10.1158/1078-0432.CCR-18-2337. PMID 30254079.
drugs.com
- "Blinatumomab (Blincyto) Use During Pregnancy". Drugs.com. 29 May 2018. Retrieved 14 March 2020.
fda.gov
fda.gov
- "FDA grants regular approval to blinatumomab and expands indication to include Philadelphia chromosome-positive B cell" (Press release). U.S. Food and Drug Administration (FDA). 12 July 2017. Retrieved 26 October 2018.
- Amgen (30 October 2012). Background Information for the Pediatric Subcommittee of the Oncologic Drugs Advisory Committee Meeting 4 December 2012 (PDF) (Report). U.S. Food and Drug Administration (FDA). Blinatumomab (AMG 103). Archived from the original (PDF) on 9 May 2017. Retrieved 16 December 2019.
nctr-crs.fda.gov
- "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
accessdata.fda.gov
- "Drug Approval Package: Blincyto (blinatumomab) Injection NDA #125557". U.S. Food and Drug Administration (FDA). 12 January 2015. Retrieved 14 March 2020.
fiercepharmamarketing.com
- Staton T (18 December 2014). "Amgen slaps record-breaking $178K price on rare leukemia drug Blincyto". FiercePharmaMarketing.
nih.gov
pubmed.ncbi.nlm.nih.gov
- Mølhøj M, Crommer S, Brischwein K, Rau D, Sriskandarajah M, Hoffmann P, et al. (March 2007). "CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis". Molecular Immunology. 44 (8): 1935–43. doi:10.1016/j.molimm.2006.09.032. PMID 17083975.
- Jen EY, Xu Q, Schetter A, Przepiorka D, Shen YL, Roscoe D, et al. (January 2019). "FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease". Clinical Cancer Research. 25 (2): 473–477. doi:10.1158/1078-0432.CCR-18-2337. PMID 30254079.
dailymed.nlm.nih.gov
- "Blincyto- blinatumomab kit". DailyMed. 19 April 2019. Retrieved 14 March 2020.
tga.gov.au
- "Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
web.archive.org
- Amgen (30 October 2012). Background Information for the Pediatric Subcommittee of the Oncologic Drugs Advisory Committee Meeting 4 December 2012 (PDF) (Report). U.S. Food and Drug Administration (FDA). Blinatumomab (AMG 103). Archived from the original (PDF) on 9 May 2017. Retrieved 16 December 2019.
wsj.com
- Loftus P (18 June 2015). "How Much Should Cancer Drugs Cost? Memorial Sloan Kettering doctors create pricing calculator that weighs factors such as side effects, extra years of life". The Wall Street Journal. Retrieved 22 June 2015.